GSK2879552, another irreversible LSD1 inhibitor, has shown antitumor activity in AML and SCLC but had to be discontinued in three clinical trials due to unfavorable risk-benefit profiles (NCT02034123, NCT02177812, and NCT02929498). Here, KDM1A is linked to small cell lung carcinoma.